HOLLISTON, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Chairman and Chief Executive Officer Jim Green will present to investors at the Southwest IDEAS Investor Conference on Thursday November 16, 2023 at The Statler in Dallas, Texas. Joining him will be Jennifer Cote, the company’s Chief Financial Officer and Treasurer.
The Company’s presentation will begin at 9:40 AM ET / 8:40 AM CT on November 16th. A replay of the presentation will be available on the Investor Relations section Harvard Bioscience website shortly after the presentation has concluded.
Harvard Bioscience will also host one-on-one meetings with investors on Thursday, November 16. To register for the conference or to schedule a one-on-one meeting, please visit https://www.threepartadvisors.com/southwest.
About Harvard Bioscience
Harvard Bioscience, Inc. is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, pharmaceutical and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. Our customers range from renowned academic institutions and government laboratories to the world’s leading pharmaceutical, biotechnology and contract research organizations. With operations in North America, Europe, and China, we sell through a combination of direct and distribution channels to customers around the world.
For more information, please visit our website at www.harvardbioscience.com.
Investor Inquiries:
Harvard Bioscience, Inc.
Investor Relations This email address is being protected from spambots. You need JavaScript enabled to view it.
(508) 893-3120
Last Trade: | US$2.24 |
Daily Change: | -0.06 -2.40 |
Daily Volume: | 78,540 |
Market Cap: | US$97.470M |
November 07, 2024 October 03, 2024 September 18, 2024 June 06, 2024 |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB